Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of TAK-861 in central disorders of hypersomnolence
CTR20243884Phase 3Active
- Sponsor
- Takeda
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oveporexton in narcolepsy type 1 (NT1), central hypersomnia, sponsored by Takeda. Started Feb 2025; status: active.
02
Drugs
oveporexton
03
Conditions
narcolepsy type 1 (NT1)central hypersomnia
Beyond the preview
Go deeper on CTR20243884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243884.